Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Iron deficiency focused Shield Therapeutics booked a narrower first-half loss, as its grew sales and lowered spending on research and development.
Pre-tax losses for the six months through June amounted to £2.5m, compared to losses of £8.0m on-year.
Revenue rose to £2.6m, up from £0.5m on-year, amid higher sales of the company's Feraccru iron deficiency treatment.
'Feraccru sales in Germany and the UK are beginning to increase significantly on the back of Norgine's enhanced promotional activities, and we have continued to deliver strong clinical data from the CKD and H2H studies,' chief executive Feraccru said.
'Since the period end, we have achieved the value-enhancing milestone of securing US FDA approval of Accrufer, the fundamental step towards being able to exploit the world's largest prescription pharmaceuticals market.'
'The board and I have great confidence in the future of Shield and we look forward to updating the market on progress with ongoing discussions relating to both potential US and Chinese commercialisation partners.'
At 8:13am: (LON:STX) Shield Therapeutics Plc share price was +3p at 169.5p